tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions
PremiumTipRanks NewswireNew Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions
2M ago
Cardiol Therapeutics Reports Positive Phase II ARCHER Trial Results for CardiolRx™
Premium
Company Announcements
Cardiol Therapeutics Reports Positive Phase II ARCHER Trial Results for CardiolRx™
2M ago
Cardiol Therapeutics Reports Financial Challenges Amid Clinical Progress
Premium
Company Announcements
Cardiol Therapeutics Reports Financial Challenges Amid Clinical Progress
2M ago
Cardiol Therapeutics Raises $16 Million Through Recent Securities Distribution
PremiumCompany AnnouncementsCardiol Therapeutics Raises $16 Million Through Recent Securities Distribution
3M ago
Cardiol Therapeutics’ Phase-3 Trial: A Potential Game-Changer in Recurrent Pericarditis Treatment
Premium
Company Announcements
Cardiol Therapeutics’ Phase-3 Trial: A Potential Game-Changer in Recurrent Pericarditis Treatment
3M ago
Cardiol Therapeutics Secures $11 Million to Advance Heart Disease Therapies
Premium
Company Announcements
Cardiol Therapeutics Secures $11 Million to Advance Heart Disease Therapies
3M ago
Cardiol Therapeutics: Promising Developments in Cardiac Disease Treatment with CardiolRx
PremiumRatingsCardiol Therapeutics: Promising Developments in Cardiac Disease Treatment with CardiolRx
5M ago
Cardiol Therapeutics Reports Q2 2025 Financial Results Amid Rising Losses
Premium
Company Announcements
Cardiol Therapeutics Reports Q2 2025 Financial Results Amid Rising Losses
5M ago
Cardiol Therapeutics to Present at Canaccord Genuity Conference
Premium
Company Announcements
Cardiol Therapeutics to Present at Canaccord Genuity Conference
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100